Delving into the Latest Updates on Zanubrutinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BRUKINSAPP, Zanubrutinib (USAN/INN), 赞布替尼

+ [4]

Target

BTK

Mechanism

BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [6]

Active Indication

Plasmablastic LymphomaFollicular LymphomaWaldenstrom's macroglobulinaemia refractory+ [47]

Inactive Indication

COVID-19liver function failureMantle cell lymphoma recurrent+ [2]

Originator Organization

BeiGene Ltd.

Active Organization

BeiGene Ltd.

Prelude Therapeutics, Inc.

Genfleet Therapeutics (Shanghai), Inc.Startup

+ [13]

Inactive Organization

MEI Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

US (14 Nov 2019),

Mantle-Cell Lymphoma

RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Special Review Project (CN), Conditional marketing approval (CN)

Login to view timeline

Structure/Sequence

Molecular FormulaC27H29N5O3

InChIKeyRNOAOAWBMHREKO-QFIPXVFZSA-N

CAS Registry1691249-45-2

This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is a bispecific monoclonal antibody that can bind to two different antigens at the same time. Odronextamab binds to CD20 found on B-cells (a type of white blood cell) and on many B-cell cancers and to CD3 on T-cells (also a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving zanubrutinib in combination with odronextamab may be safe, tolerable and/or effective in treating patients with Richter's transformation.

Start Date14 Aug 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06803693

/ Not yet recruitingPhase 2IIT

A Study to Evaluate the Efficacy and Safety of Genotype-guided Targeted Agents in Combination with POLA-RCHP VERSUS POLA-RCHP in Patients with Previously Untreated Diffuse Large B-cell Lymphoma

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Start Date01 Apr 2025

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

NCT06730542

/ RecruitingPhase 1IIT

Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma

The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.

Start Date31 Mar 2025

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Zanubrutinib

Login to view more data

100 Translational Medicine associated with Zanubrutinib

Login to view more data

100 Patents (Medical) associated with Zanubrutinib

Login to view more data

574

Literatures (Medical) associated with Zanubrutinib

01 Dec 2025·Blood Research

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations

Article

Author: Lim, Joo Han ; Kim, Jinchul ; Lee, Moon Hee ; Cho, Jinhyun

Abstract:

Purpose:

This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p deletion and TP53 mutations.

Methods:

We conducted a systematic literature review to identify all publicly available randomized controlled trials (RCTs) using PubMed, EMBASE, the Cochrane database, and meeting abstracts published through December 2023. A Bayesian network meta-analysis was performed to estimate the hazard ratios (HRs) for progression-free survival (PFS) with 95% confidence intervals (CIs) and to determine the ranking of the included regimens.

Results:

Twelve trials involving 4,437 patients and 13 treatment options were included in the meta-analysis. Venetoclax plus rituximab and zanubrutinib emerged as the most effective treatments for the overall R/R CLL population, showing the lowest PFS HR (HR 0.62, 95% CI 0.32–1.20 and HR 0.65, 95% CI 0.49–0.86, respectively) versus ibrutinib, and were ranked as the best agent (surface under the cumulative ranking curve [SUCRA] value of both 90%, respectively) among the included drugs. In the 17p deletion/TP53 mutation subgroup, zanubrutinib demonstrated the most favorable efficacy (HR 0.52, 95% CI 0.31–0.88 versus ibrutinib) with the highest SUCRA value (97%). In patients without these mutations, venetoclax plus rituximab was the most effective (HR 0.49, 95% CI 0.26–0.94 versus ibrutinib) with a SUCRA value of 94%.

Conclusion:

Our findings highlight the superior efficacy of venetoclax plus rituximab and zanubrutinib for treating R/R CLL and confirm that the role of each regimen may vary depending on the clinically significant mutations.

01 Mar 2025·HEMATOLOGICAL ONCOLOGY

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study

Article

Author: Liu, Xiaodan ; Yan, Yuting ; Li, Saisai ; Su, Zhan ; Wang, Shibo ; Wang, Chuanlei ; Fan, Fuli ; Cui, Shuxia

ABSTRACT:

This study compares the safety profiles of two Bruton's tyrosine kinase (BTK) inhibitors, Ibrutinib and Zanubrutinib, in patients with chronic lymphocytic leukemia (CLL). While Ibrutinib has transformed CLL treatment, it is associated with significant adverse events (AEs). Zanubrutinib, a second‐generation BTK inhibitor, offers potential for improved safety. In this prospective study, 200 CLL patients were enrolled, with 100 receiving Ibrutinib and 100 receiving Zanubrutinib. Baseline characteristics such as age, sex, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, and genetic factors were evaluated. AEs and serious AEs (SAEs) were tracked and graded using the Common Terminology Criteria for Adverse Events (CTCAE). Multivariate logistic regression models were conducted to determine predictors of SAE and AEs grade ≥ 3. Adjusted odds ratio (aOR) and 95% confidence interval (CI) were reported. The mean ages of the Ibrutinib and Zanubrutinib groups were 49.65 and 49.16 years, respectively (p = 0.285). The Zanubrutinib group had a higher percentage of patients with worse ECOG status (71% vs. 57%, p = 0.039). Fewer Zanubrutinib patients experienced severe AEs (4% vs. 9%, p = 0.152) or SAEs (8% vs. 17%, p = 0.054). Neutropenia occurred only in the Ibrutinib group (3%). Subgroup analysis showed a higher complication rate with Zanubrutinib in non‐refractory patients (11.40% vs. 5.26%, p = 0.065). Stage III CLL was a protective factor of grade ≥ 3 AEs (aOR = 0.007; 95% CI: 0.0003–0.1829) and SAE (aOR = 0.015; 95% CI: 0.001–0.177). While ECOS status (2 vs. 3) resulted in reduced risk of SAE, chromosome 17p deletion emerged as the main risk factor of SAE (aOR = 6.40; 95% CI: 1.33–30.79). Zanubrutinib demonstrated a more favorable safety profile than Ibrutinib, with fewer severe adverse events. It may be a safer alternative for CLL patients, particularly those at higher risk for complications from BTK inhibitors. However, these differences stemmed from variability in baseline clinical characteristics rather than the interventions themselves.

01 Feb 2025·Analytical and Bioanalytical Chemistry

Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma

Article

Author: Song, Zaiwei ; Zhao, Rongsheng ; Xiong, Xin ; Zhang, Xu ; Ma, Yi ; Jiang, Dan ; Hu, Yang ; Dong, Fei ; Bing, Hao

Bruton's tyrosine kinase inhibitors (BTKis) exhibit significant interindividual pharmacokinetics, making therapeutic drug monitoring (TDM) a promising approach for personalized therapy. However, simultaneous quantification of multiple BTKis poses technical challenges. A unified protocol for BTKis detection would be clinically desirable. Herein, we developed and validated a novel LC-MS/MS method for the simultaneous analysis of four BTKis including ibrutinib (IBR), zanubrutinib (ZAN), orelabrutinib (ORE), and acalabrutinib (ACB) and active metabolite of IBR and ACB (DIH and ACBM, respectively) in human plasma. The samples were prepared by liquid-liquid extraction using tert-butyl methyl ether. Ibrutinb-d4 (IS) was used as an internal standard. Chromatographic separation was obtained on an XBridge C18 column and connected to an LC-30AD system coupled to an API 4000⁺ mass spectrometer. The mobile phase comprised 10 mM ammonium acetate containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. The optimized multiple reaction monitoring transitions of m/z 441.4 → 138.3, 475.4 → 304.2, 472.5 → 455.5, 428.3 → 411.5, 466.1 → 372.2, 482.2 → 388.4, and 445.5 → 142.5 were selected to inspect IBR, DIH, ZAN, ORE, ACB, ACBM, and IS, respectively. The method exhibited linearity from 1 to 1000 ng/mL (r > 0.99) for all analytes, with intra-day and inter-day precision of 1.8 to 9.7% and accuracy below 15%. Recovery ranged from 90.4 to 113.6%, and matrix effect varied from 89.3 to 111.0%. All compounds demonstrated stability under relevant conditions. Application of the method to 57 blood samples from 18 patients demonstrated high interpatient variability, with ORE plasma concentrations ranging from 25.6 to 89.9%. The validated LC-MS/MS method provides a feasible, specific, and rapid approach for quantification of BTKis in clinical settings. Simultaneous determination of four BTKis and their metabolites in a single extraction process and chromatographic run reduces analysis time, cost, and resources. The observed variability among individuals highlights the value of TDM for personalized treatment.

173

News (Medical) associated with Zanubrutinib

21 Jan 2025

·www.echemi.com

AstraZeneca's Calquence Gains FDA Approval for First-Line Treatment of MCL

Recently, AstraZeneca announced that its BTK inhibitor, Calquence (acalbrutinib), has received FDA approval for a new indication. It is now authorized for use in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not suitable for autologous stem cell transplantation. This approval marks Calquence as the first BTK inhibitor approved for first-line therapy in MCL. Approval Based on Positive Clinical Results The FDA's decision was primarily based on positive outcomes from a Phase III clinical trial assessing Calquence in combination with standard treatment (SOC: bendamustine + rituximab). The study evaluated the efficacy and safety of this regimen in MCL patients aged 65 years or older who had not received prior treatment. The trial's main endpoint was progression-free survival (PFS). Results indicated that patients receiving Calquence experienced a statistically and clinically significant improvement in PFS compared to the SOC group, with median PFS durations of 66.4 months versus 49.6 months (HR=0.73, P=0.0160). Additionally, there was a positive trend toward improved overall survival (OS) in the Calquence group (HR=0.86, P=0.27). Overview of MCL and BTK Inhibitors MCL is a rare form of B-cell non-Hodgkin lymphoma characterized by both indolent and aggressive clinical-pathological features. Over the past decade, several new therapies have been developed for MCL, particularly Bruton’s tyrosine kinase inhibitors (BTKis), which have demonstrated significant efficacy in treating these patients. Currently, five BTK inhibitors are available globally for MCL treatment: the first-generation ibrutinib and the second-generation agents acalbrutinib, zanubrutinib, obuibrutinib, and the non-covalent BTK inhibitor pirtobrutinib. Calquence has gained a competitive edge as it becomes the first approved BTK inhibitor for first-line treatment in MCL. Its main competitor, BeiGene's zanubrutinib, is still in Phase III trials for first-line MCL treatment. Ibrutinib has shown a median PFS benefit of nearly 28 months, which is significantly higher than the 17 months observed for acalbrutinib in the ECHO trial. However, despite its success in PFS, ibrutinib has not translated this benefit into improved overall survival, preventing its approval for first-line therapy. AstraZeneca's Calquence approval represents a significant advancement in the treatment landscape for MCL, offering a new option for patients who cannot undergo stem cell transplantation. With its proven efficacy in a clinical setting, Calquence is poised to play a crucial role in the management of this challenging disease, further establishing its position in the evolving field of oncology.

Clinical ResultPhase 3Drug ApprovalCell TherapyAccelerated Approval

20 Jan 2025

·www.pharmaceutical-technology.com

AstraZeneca secures first BTK approval in first-line mantle cell lymphoma

Calquence is forecast to generate up to $4.7bn in sales by 2030, as per GlobalData intelligence. Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma (MCL). This approval makes Calquence the first BTK inhibitor available for adults with untreated MCL who are unsuitable for autologous haematopoietic stem cell transplantation (HSCT) and allows its use in combination with chemoimmunotherapy. The FDA granted approval based on data from the Phase III ECHO trial (NCT02972840). The randomised, double-blind, placebo-controlled study enrolled 598 patients aged 65 or older with untreated MCL who were unsuitable for HSCT. Patients were randomised to receive Calquence with chemotherapy bendamustine and Biogen and Genentech’s Rituxan (rituximab) or placebo plus bendamustine and Rituxan. Efficacy was measured by progression-free survival (PFS) and evaluated by an independent review committee. The median PFS was 66.4 months in the Calquence plus BR arm, compared to 49.6 months in the placebo plus bendamustine and Rituxan arm. The trial demonstrated a 27% improvement in PFS for Calquence over placebo. MCL is a rare and aggressive subtype of non-Hodgkin lymphoma, often diagnosed in later stages and characterised by the malignant transformation of B lymphocytes in the lymph node mantle zone. Calquence, a next-generation selective and irreversible BTK inhibitor, binds covalently to the BTK active site to inhibit enzymatic activity, suppressing the proliferation and survival of malignant B cells. AstraZeneca’s Calquence now holds a first-mover advantage in the treatment-naive MCL market, outpacing competitors such as BeiGene’s Brukinsa (zanubrutinib), Eli Lilly’s Jaypirca (pirtobrutinib), InnoCare’s Inokai (orelabrutinib), all of which remain in late-stage clinical trials for this indication. AbbVie and Johnson & Johnson’s (J&J’s) Imbruvica (ibrutinib) was previously positioned to lead the market but lost its accelerated approval in 2023 after the Phase III SHINE trial (NCT01776840) showed no overall survival benefit and a 7% increase in mortality risk for Imbruvica-treated patients. GlobalData projects that Calquence could generate up to $4.7bn in sales by 2030. With this FDA approval, AstraZeneca is poised to capitalise on its lead in the competitive BTK inhibitor market. GlobalData is the parent company of Pharmaceutical Technology.

Phase 3Drug ApprovalClinical ResultImmunotherapyAccelerated Approval

17 Jan 2025

·endpts.com

AstraZeneca wins BTK race to market in first-line mantle cell lymphoma

AstraZeneca’s Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug may now be used in combination with chemoimmunotherapy in adults who can’t be treated with autologous hematopoietic stem cell transplantation. The FDA granted the accelerated approval based on the 27% benefit over placebo on progression-free survival Calquence demonstrated in the Phase 3 ECHO trial last June . This means AstraZeneca can immediately start to capitalize on the lead it has over its nearest rival, BeiGene, whose BTK inhibitor Brukinsa, is still in Phase 3 in first-line MCL. However, there is still a question mark over ECHO’s overall survival endpoint. Data here are not yet mature and findings with Johnson & Johnson and AbbVie’s first-gen BTK, Imbruvica, set a tricky precedent. Imbruvica achieved a median PFS benefit of nearly 28 months in its Phase 3 first-line MCL trial, more than the nearly 17 months the second-gen Calquence showed in ECHO. But Imbruvica’s PFS success did not translate into an improvement in OS, and Imbruvica was not approved for first-line disease. More drastically, in April 2023 J&J withdrew the drug from the US market in the second line setting. It is not clear when full OS data from Calquence’s trial might emerge, though the earlier ECHO data showed a positive trend on this endpoint. PFS data from the Phase 3 trial of Brukinsa in first-line MCL will likely not appear for another couple of years. The study is testing BeiGene’s BTK in combination with Rituxan versus a bendamustine-Rituxan combo. Calquence obtained accelerated US approval in second-line MCL in 2017; on Thursday this was converted into full approval.

Phase 3Drug ApprovalClinical ResultImmunotherapyAccelerated Approval

100 Deals associated with Zanubrutinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11422	Zanubrutinib	L01XE	DB15035

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Plasmablastic Lymphoma	JP	BeiGene Ltd.	27 Dec 2024
Follicular Lymphoma	TH	BeiGene Ltd.	07 Feb 2024
Waldenstrom's macroglobulinaemia refractory	TH	BeiGene Ltd.	07 Feb 2024
Recurrent Follicular Lymphoma	EU	BeiGene Ireland Ltd.	17 Nov 2023
Recurrent Follicular Lymphoma	IS	BeiGene Ireland Ltd.	17 Nov 2023
Recurrent Follicular Lymphoma	LI	BeiGene Ireland Ltd.	17 Nov 2023
Recurrent Follicular Lymphoma	NO	BeiGene Ireland Ltd.	17 Nov 2023
Marginal zone lymphoma recurrent	US	BeiGene USA, Inc.	19 Jan 2023
Refractory Marginal Zone Lymphoma	BR	BeiGene Ltd.	10 Nov 2022
Refractory Follicular Lymphoma	GB	BeiGene Ltd.	06 Dec 2021
Marginal Zone B-Cell Lymphoma	UY	BeiGene Ltd.	28 Apr 2021
Waldenstrom Macroglobulinemia	CA	BeiGene Ltd.	30 Mar 2021
Chronic Lymphocytic Leukemia	CN	BeiGene (Suzhou) Co. Ltd.	03 Jun 2020
Small Lymphocytic Lymphoma	CN	BeiGene (Suzhou) Co. Ltd.	02 Jun 2020
Mantle-Cell Lymphoma	US	BeiGene USA, Inc.	14 Nov 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, Membranous	Phase 3	US	BeiGene (Suzhou) Co. Ltd.	17 Apr 2023
Glomerulonephritis, Membranous	Phase 3	CN	BeiGene (Suzhou) Co. Ltd.	17 Apr 2023
Glomerulonephritis, Membranous	Phase 3	CZ	BeiGene (Suzhou) Co. Ltd.	17 Apr 2023
Glomerulonephritis, Membranous	Phase 3	GB	BeiGene (Suzhou) Co. Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	US	BeiGene Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	CN	BeiGene Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	AR	BeiGene Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	BR	BeiGene Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	CA	BeiGene Ltd.	17 Apr 2023
Idiopathic Membranous Glomerulonephritis	Phase 3	CZ	BeiGene Ltd.	17 Apr 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03734016 (ALPINE, Pubmed \| Blood)	Phase 3	Chronic Lymphocytic Leukemia del(17p) \| TP53 mutation	652	Zanubrutinib	hvqwuoatsx(qfyggfjbmi) = no cardiac deaths were reported with zanubrutinib vs 6 cardiac deaths with ibrutinib efjumqmbwb (wntujsvkrt ) View more	Positive	26 Dec 2024
				Ibrutinib
NCT04277637 (BGB-11417-101, ASH2024) Manual	Phase 1	Chronic Lymphocytic Leukemia	112	zanubrutinib + Sonrotoclax 160 mg	vbdadbtprb(hvfcvpaaif) = neutropenia (41%), contusion (38%), COVID-19 (30%), and diarrhea (29%; 78% had grade 1 events). Neutropenia was the most common grade ≥3 TEAE (n=29, 26%). fsqzubxrfg (agjfdoossk )	Positive	09 Dec 2024
				zanubrutinib + Sonrotoclax 320 mg
NCT04116437 (BGB-3111-215, ASH2024) Manual	Phase 2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia \| Waldenstrom Macroglobulinemia ... View more	35	Zanubrutinib	wouufhpoee(sdchsxbewq) = mbelgomfyi geaxpouyjp (xvuuqgiqpe ) View more	Positive	09 Dec 2024
ASH2024 Manual	Phase 1	Diffuse Large B-Cell Lymphoma	22	Polatuzumab Vedotin+Zanubrutinib+Rituximab+Lenalidomide	whrjiygosc(yoaoswncqq) = debawyuval ojrmbukhlo (icivitqoni ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	ZR-CHOP	mxlmxaovow(iumgbvfela) = 92.9% of patients experienced any-grade treatment emergent adverse events (TEAEs), with the majority being hematological toxicities iyustiggju (klvwrfzumq ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Zanubrutinib 160 mg	xshkylzeov(tsvuglvevj) = Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 74% of patients; the most common TEAEs were neutrophil count decreased (58%), white blood cell count decreased (29%), and lymphocyte count decreased (20%). TEAEs led to treatment discontinuation in 7 patients (11%) and death in 2 patients (3%; cardiopulmonary failure, n=1; pneumonia, n=1; neither considered related to study treatment) pmzrnkstpf (myopgxrlct )	-	09 Dec 2024
				Lenalidomide 25 mg
ASH2024	Not Applicable	Chronic Lymphocytic Leukemia	-	Zanubrutinib 160 mg	iokzgcpffp(yxxqnqofow) = mwtsrzhiky hnuxdpymot (njvazlvxjg ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Chronic Lymphocytic Leukemia	-	Zanubrutinib monotherapy	memfncsemg(gtxxwfommz) = occurred in 84.1% of patients fykdbvvnfn (kkkbczjfvq ) View more	-	08 Dec 2024
				Zanubrutinib + Obinutuzumab
ASH2024	Not Applicable	Follicular Lymphoma	-	Zanubrutinib plus Obinutuzumab	cmiijtiphu(dhfyclzfaf) = bzzonrmxiv abkoqnwdao (yyyakqflrr, 16.1 - NE)	-	08 Dec 2024
				Obinutuzumab alone	cmiijtiphu(dhfyclzfaf) = kmidkcuaxj abkoqnwdao (yyyakqflrr, 6.5 - 13.8)
NCT03336333 (SEQUOIA, ASH2024)	Phase 3	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma del(17p) \| IGHV mutation status	479	Zanubrutinib	dybigytqsk(fvdpdhlvkv) = kcclmpgkyz ztzsgrexhs (fkbbpiqzbw ) View more	Positive	08 Dec 2024
				Bendamustine + Rituximab	dybigytqsk(fvdpdhlvkv) = bqfodvjlzp ztzsgrexhs (fkbbpiqzbw ) View more